Navigation Links
Genes linked to treatment resistance in children with leukemia

Today, the most common childhood cancer is cured in about 80 percent of patients; only forty years ago, this number was closer to five percent. In efforts to further increase the survival rate, researchers from St. Jude Children's Research Hospital, the University of Tennessee, and the University of Chicago studied how an individual's genetics might play a role in the effectiveness of chemotherapy drugs. Their findings will be published in the June 15, 2005, issue of Blood, the official journal of the American Society of Hematology.

The researchers studied 246 children with acute lymphoblastic leukemia (ALL), all of whom were assigned to one of two groups that determined the intensity of therapy. Patients with poorer prognostic factors ?130 children ?were assigned to a high-risk group; the remaining children were enrolled in the lower-risk arm.

In a process known as genotyping, DNA was extracted from the normal blood cells of each child and screened for sixteen common genetic variations. The studied genes code for enzymes which are involved in the metabolism and activity of chemotherapy drugs in the body, and were therefore likely to have effects on treatment outcomes.

In the analysis of the high-risk group, the GSTM1 non-null genotype was associated with hematological relapse, a recurrence of the cancer in the blood and bone marrow and the most common reason for treatment failure in childhood ALL. This risk was further increased if the child also had a TYMS 3/3 genotype. No genotype was associated with hematological relapse among patients in the lower-risk arm of the study.

The researchers also looked for evidence of leukemia in each patient's central nervous system (CNS), a region that is vulnerable to infiltration by cancer cells. Genetic variations may have particular impact on how drugs penetrate the "blood-brain" barrier that protects the CNS. For patients in the high-risk arm, the VDR FokI genotype was found to be prognostic for CNS relapse, especially when combined with a VDR intron 8 genotype. In the low-risk group, the TYMS 3/3 genotype was a risk factor.

For children with these unfavorable genotypes, a potential solution may be using drugs that are not affected by these particular enzymes or increasing the dosage of drugs that are. And, in the future, a simple blood test may be all that's needed to make that determination.

"This research showcases a new direction for cancer treatment ?personalized chemotherapy based on the genetics of the patient," said Mary Relling, Pharm.D., St. Jude faculty member and lead study author. "In our study, several common genetic variations were found to predict the outcomes of leukemia patients, demonstrating that genotyping may become an important tool for tailoring treatment and improving an individual's chance of a cure."


'"/>

Source:American Society of Hematology


Related biology news :

1. Genes In The Interferon System Important In Systemic Lupus Erythematosus
2. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
3. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
4. Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer
5. Where Bacteria Get Their Genes
6. Noise And Delays Explain Why Some Genes Oscillate In Activity
7. Genes involved in biofilms
8. Genes involved in cell growth and cell division identified
9. Genes affecting blood pressure change as children become adults
10. Genes discovered that allow gum disease bacterium to invade arteries
11. Genes and genius: Researchers confirm association between gene and intelligence
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN ... STANDARD: QIA) today announced the U.S. launch of its ipsogen ... cleared by the U.S. Food and Drug Administration as a qualitative in vitro ... extracted from EDTA whole blood.* ... ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a ... the world’s food supply through enhancement of the gut microbiota, today announced the closing ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number of ...
Breaking Biology Technology: